Research Article

Significance of CYP3A4*1G and OPRM1 A118G Polymorphisms in Postoperative Sufentanil Analgesia in Women of Different Ethnicities

Chunying Zhang,1 Qiyuan Zheng,2 Fengting Pan,1 Ting Wang,3 Yalin Zhao,3 Zhaoguang Xiao,3 and Zehan Huang1

1Department of Anesthesiology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China
2Department of Anesthesiology, Pingguo People’s Hospital, Baise, Guangxi 533000, China
3Department of Anesthesiology, Graduate School of Youjiang Medical University for Nationalities, Baise, Guangxi 533000, China

Correspondence should be addressed to Zehan Huang; huangzehan@ymun.edu.cn

Received 19 April 2022; Revised 6 June 2022; Accepted 8 June 2022; Published 28 June 2022

Academic Editor: Ahmed Faeq Hussein

Copyright © 2022 Chunying Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To investigate the association between CYP3A4*1G and OPRM1 A118G gene polymorphisms and postoperative analgesia with sufentanil in women of Zhuang ethnicity from western Guangxi, China. Methods. Forty-eight Chinese Zhuang women who underwent elective myomectomy under general anesthesia in our hospital from January 2019 to December 2020 were selected, and another 47 Chinese Han patients in the same period were selected as the control subjects. CYP3A4*1G and OPRM1 A118G gene polymorphisms as well as sedation and pain scores at different time points after surgery were compared between the two groups of patients to analyze the relationship between the degree of pain and dosage of sufentanil and to analyze the effect of gene polymorphisms on the occurrence of adverse reactions. Results. The frequencies of *1/*1G and *1G/*1G genotypes, allele 1 of CYP3A4 and genotypes AA, and allele A of OPRM1 A118G in Zhuang patients were lower than those in Han patients, while the frequencies of *1/*1, allele 1 of CYP3A4 and genotypes AG, genotypes GG, and allele G of OPRM1 A118G were higher in Zhuang patients. There was no significant difference in the Ramsay and VAS scores between the two groups at different time points after surgery, but the sufentanil use in Zhuang patients was higher than in Han patients at different time points after surgery. In addition, sufentanil use was highest in Zhuang patients with the *1/*1G genotype of the CYP3A4 gene. No significant difference was found in the incidence of adverse reactions during analgesia between the two groups. Conclusion. CYP3A4*1G could be associated with postoperative sufentanil analgesia in Zhuang patients in western Guangxi and should be considered when developing personalized analgesia regimens.

1. Introduction

Sufentanil, a derivative of fentanyl, is one of the commonly used opioids for postoperative analgesia in China. However, scholars have found significant individualized differences in the dosage of sufentanil for postoperative analgesia and the incidence of adverse reactions after use, which may be related to the patient’s genetic background [1]. Single nucleotide polymorphisms (SNPs) refer to the differences in the nucleotide sequence of a gene among individuals [2]. Previous studies have demonstrated that SNPs could lead to individualized differences in analgesic effects by affecting the pharmacokinetics of sufentanil [3]. Cytochrome P450 (CYP) 3A4 was shown to be responsible for sufentanil N-dealkylation and generation of norfentanyl, but significant differences were observed in CYP3A4 enzyme activity in different individuals [4], which may have been related to genetic factors [5].

CYP3A4*1G is a newly discovered allele in 2014, accounting for a prevalence of 22.1% in the Han population. Studies have shown that CYP3A4*1G gene mutation could enhance the efficacy of intravenous fentanyl in women [6],
2. Materials and Methods

and patients with this gene mutation required a higher sufentanil dosage for analgesia 24 hours after surgery.

Sufentanil mainly acts on human μ opioid receptors (MOR), and in China, the OPRM1 A118G SNP has the highest incidence in encoding MOR, which produces a non-synonymous amino acid substitution [7]. Polymorphisms at this site can cause the loss of a glycosylated site in the extracellular N-terminal region, thus seriously affecting the function of OPRM1 protein and leading to a significant decrease in the analgesic potency of sufentanil [8].

At present, there are few reports on the SNP distribution of CYP3A4*1G and OPRM1 A118G and the relationship between their polymorphisms and postoperative sufentanil analgesia in Zhuang women in western Guangxi, China. Therefore, this study is aimed at exploring the genetic factor associated with individual differences in the analgesic effect of sufentanil, providing a scientific theoretical basis for guiding the selection of postoperative analgesia regimens for patients of different ethnic groups and different genotypes, and ultimately improving the analgesic effect and reducing the occurrence of potentially related adverse reactions.

2. Materials and Methods

2.1. Study Subjects. A total of 48 female patients of Zhuang ethnicity who underwent elective myomectomy under general anesthesia in our hospital from January 2019 to December 2020 were selected as the study subjects, and 47 Han female patients in the same period as the controls. The general data of the patients were recorded. The inclusion criteria of the study were as follows: (1) age ≥ 18 years, Zhuang nationality; (2) underwent elective myomectomy under general anesthesia and received sufentanil for analgesia 48 hours after surgery; (3) conformed to the American Society of Anesthesiologists (ASA) physical status I or II; and (4) provided informed consent and volunteered to participate in the study.

Exclusion criteria were as follows: (1) had severe heart, liver, kidney, and other organic diseases; (2) drug contraindications or drug allergy; (3) diabetes, hypertension, history of chronic pain, or use of analgesic drugs; (4) drugs that affected the CYP3A enzyme activity were taken within 1 month before surgery; (5) patients with disturbance of consciousness or mental disorders, depression, or anxiety and could not cooperate with the treatment; and (6) cases with incomplete information. This study was approved by the medical ethics committee of the Affiliated Hospital of Youjiang Medical University for Nationalities (approval no.: YYFY-LL-2019-008; Guangxi, China).

2.2. Anesthesia. The patients were made to fast for 8 hours and water deprivation for 4 hours before surgery. Electrocardiogram, heart rate, blood pressure, oxygen saturation, and electrical activity in the brain were observed using a monitor after entering the operating room. The patients’ upper limb venous access was used for drop infusion of sodium chloride injection, and conventional oxygen inhalation was performed via a mask at an oxygen flow rate of 3L/min. Penehyclidine hydrochloride (0.01 mg/kg) and midazolam (0.05 mg/kg) were injected 30 min before induction of anesthesia. Their heart rate, blood pressure, and oxygen saturation were recorded again after adequate analgesia.

2.2.1. Induction of General Anesthesia. Propofol (0.5 mg/kg) with the effect-site concentration of 3 μg/ml was intravenously injected. After the loss of consciousness, the patients were intravenously injected with remifentanil (2 μg/kg) and cisatracurium besylate (0.15 mg/kg). For muscle relaxation, an intravenous injection of succinylcholine (1.5 mg/kg) was given after the patients fell asleep. Then, the patients were given mechanical ventilation at 8-10 ml/kg through orotracheal intubation.

2.2.2. Maintenance of Anesthesia. With a continuous intravenous infusion of remifentanil (0.1-0.2 μg/kg/min) and propofol (6-8 mg/kg/h), the depth of anesthesia was adjusted by adjusting the infusion rate. During anesthesia, in case of systolic blood pressure ≤ 80 mmHg lasting for more than 1 min, the infusion rate could be accelerated to correct hypotension. If the condition was not relieved, 5-10 mg of ephedrine was intravenously injected. The duration of anesthesia was recorded. All anesthetic drugs were stopped postoperatively, and 0.5 mg of atropine and 1 mg of neostigmine were given to antagonize the residual effects of the muscle relaxant. The patients were extubated after regaining consciousness and were assisted to normal spontaneous breathing.

2.3. Postoperative Analgesia. The CADD-Legacy 6300 infusion pump was used, with the drug formula for analgesia: sufentanil 0.1 μg, droperidol 5.0 μg, and normal saline added to 100 ml. Settings of patient-controlled intravenous analgesia (PCIA) were as follows: a basic dose of sufentanil: 0.5 μl/h, an additional dose of sufentanil: 2 μl/time, locking time: 5 min, the number of effective press per hour: 7 times, and maximum dose of sufentanil per hour: 145 μg.

2.4. Outcome Measures. At 6 hours (T1), 24 hours (T2), and 48 hours (T3) after infusion of sufentanil, the analgesic effects of sufentanil and pain degree of patients were evaluated using the Ramsay scale [9] and visual analog scale (VAS) [10], respectively. The former is a 6-point scaling detailed as follows: 1 point: anxious and agitated or restless; 2 points: oriented, cooperative, and tranquil; 3 points: response to commands only; 4 points: asleep and brisk response to a light glabellar tap; 5 points: asleep and sluggish response to a light glabellar tap; and 6 points: asleep and no response to stimuli. The latter is a 10-point scale, where 0 represents no pain and 10 represents unbearable pain.

2.5. Incidence of Adverse Reactions. The incidence of nausea, vomiting, pruritus, and respiratory depression during analgesia was recorded for all patients, using the following formula: incidence of adverse reactions (%) = (number of cases with adverse reactions/total cases) × 100%.

2.6. Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RELP). Before surgery, 3 ml of peripheral venous blood was extracted from each patient, then placed in an EDTA anticoagulant tube, and stored in a
refrigerator at 4°C. Subsequently, on completion of DNA extraction from whole blood according to the instructions of the DNA extraction kit (Tiangen, China) within 7 days, the DNA was amplified using a quantitative fluorescence PCR kit (Takara, Japan). The reaction conditions of PCR were as follows: denaturation for 5 min at 94°C; 40 cycles of denaturation for 30 s at 94°C, annealing for 60 s at 60°C, extension for 60 s at 72°C, and extension for 10 min at 72°C. The PCR products were removed and stored at 4°C for testing. The primer sequences are shown in Table 1. Afterward, the amplified products were digested using MspI endonuclease (Bio Labs, Singapore) and placed in a water bath for 16 h at 37°C. After that, electrophoresis was performed with a 2% gel, and digestion results were observed using a gel imager (Bio-rad, USA).

For CYP3A4*1G, *1/*1 represented wild-type, *1/*1G represented heterozygous mutation, and *1G/*1G represented homozygous mutation. For OPRM1 A118G, AA represented wild-type, AG/GA represented heterozygous mutation, and GG represented homozygous mutation.

2.7. Statistical Analysis. All analyses were performed using the SPSS 22.0 software. The χ² test was used to evaluate whether the genotype distribution and allele distribution conformed to Hardy-Weinberg equilibrium. Continuous variables were analyzed with the t-test and expressed as mean ± standard deviation (mean ± SD), while categorical variables were analyzed with the χ² test and expressed as n (%). P < 0.05 was considered statistically significant.

3. Results

3.1. General Data of Patients from the Two Ethnic Groups. The general data of the patients were recorded. No significant differences were identified in height, weight, age, anesthesia time, and operation time between the two ethnic groups (Table 2, P > 0.05), indicating that the two groups of patients were comparable.

3.2. Comparison of Genotype Frequency and Allele Frequency between the Two Groups. Here, the genotype frequency and allele frequencies of CYP3A4*1G and OPRM1 A118G in the two groups were compared. Compared with Han women, Zhuang women had higher frequencies of *1/*1 genotype and allele *1 and lower frequencies of *1/*1G and *1G/*1G genotypes. The frequency of allele *1 of the CYP3A4*1G gene was significantly higher than that of allele *1G in Zhuang women (Table 3). Additionally, compared with Han women, Zhuang women had higher frequencies of AG and GG genotypes and allele G of the OPRM1 A118G gene (Table 4). Collectively, significant differences were observed between the two groups in the genotype frequency and allele frequency of CYP3A4*1G and OPRM1 A118G (P < 0.05).

3.3. Comparison of Ramsay and VAS Scores at Different Time Points after Surgery between the Two Groups. The Ramsay score and VAS score were used to evaluate the patients' postoperative analgesic effect and pain degree, respectively. The results showed no significant difference in Ramsay score and VAS score between the Han and Zhuang patients at different time points (Figure 1).

3.4. Sufentanil Use at Different Time Points after Surgery in Zhuang Patients Was Greater than in Han Patients. Further analysis on the use of sufentanil between the two groups of patients at T1, T2, and T3 time points revealed a higher sufentanil consumption in Zhuang patients at all three time points (Figure 2) suggesting that sufentanil consumption could be related to CYP3A4*1G and OPRM1 A118G genotypes.

3.5. Sufentanil Use Was Different in Zhuang Patients with Different Genotypes. Further, we analyzed the relationship between sufentanil consumption and different genotypes of CYP3A4*1G and OPRM1 A118G in Zhuang patients. Our results showed that sufentanil consumption was higher in patients with *1/*1 genotype of CYP3A4*1G gene compared with *1/*1G and *1G/*1G genotypes at T1-T3 time points. However, sufentanil consumption in Zhuang patients with different OPRM1 A118G genotypes was not significantly different at all three time points (P > 0.05) (Figure 3).

3.6. Comparison of Incidence of Adverse Reactions during Analgesia between the Two Groups. According to the statistical analysis of the incidence of adverse reactions during analgesia in the two groups, no significant difference was identified between Zhuang and Han patients (Table 5).

4. Discussion

Sufentanil, a N-4 thiényl derivative of fentanyl, is a highly selective MOR μ-receptor agonist with a high affinity to opioid receptors. It has stronger analgesic activity than morphine and fentanyl and significantly affects postoperative analgesia in patients [11, 12]. Sufentanil is characterized by significant effects on hemodynamics, long duration of action, and low incidence of adverse reactions and is widely used in postoperative analgesia. However, in practical application, individual differences were observed in the dosage and analgesic effects of sufentanil, leading to personalized analgesic management. Studies have found [13, 14] that genetic factors were a vital cause of the observed individual differences, which were closely linked to gene polymorphisms. Therefore, it is of great clinical significance to clarify the effects of gene polymorphism on the postoperative analgesic effect of sufentanil for better individualized analgesia with sufentanil.

Sufentanil was shown to cause its effect via the following process: in vivo absorption, liver first-pass effect, transport,
reaching the target organ, and binding to the receptor for analgesia [15], in which MOR and CYP were found to be involved as well. CYP is mainly present in the endoplasmic reticulum of liver cells and the mucous membranes of the digestive system and can be involved in the metabolism of more than half of clinical drugs [16]. CYP3A4 has been confirmed to play an important role in the metabolism of sufentanil. CYP3A4*1G (rs 2242480) in CYP3A4 intron 10 is an allele of CYP3A4. Mutations in CYP3A4*1G are associated with decreased mRNA levels of CYP3A4, leading to a decrease in the metabolic rate of sufentanil and a relative reduction in the dosage [17]. OPRM1 A118G (rs 1799971) SNP, the most studied SNP, refers to the mutation of adenylate to guanylate at 118 bp of exon 1 [18]. OPRM1 A118G SNP results in a decrease in the number and effects of opioids.

In this study, we detected the SNPs of CYP3A4*1G and OPRM1 A118G in Zhuang women in western Guangxi and analyzed the correlation between their SNPs and postoperative analgesia using sufentanil. We found significant differences in genotype frequency and allele frequency between Zhuang women and Han women. This result is consistent with that of Liang et al. [19], who suggest the presence of SNPs in CYP3A4*1G and OPRM1 A118G genes in Zhuang and Han women. Further, no significant differences were found in Ramsay score and VAS score at different time points after surgery between the two groups. However, at different time points after surgery, our results showed that the use of sufentanil was greater in Zhuang women than in Han women, indicating that women of different ethnic groups demonstrated different requirements for sufentanil consumption to achieve the same sedation and pain levels. Further, a significant difference in sufentanil consumption among Zhuang patients

Table 2: General data of patients of different ethnic groups.

| Group | Case (n) | Age (year) | Height (cm) | Weight (kg) | Anesthesia time (min) | Operation time (min) |
|-------|---------|------------|-------------|-------------|----------------------|----------------------|
| Zhuang | 48      | 47.27 ± 6.65 | 155.35 ± 6.04 | 55.00 ± 6.50 | 103.02 ± 22.02      | 131.08 ± 21.97       |
| Han    | 47      | 46.21 ± 6.03 | 155.09 ± 1.59 | 55.30 ± 7.63 | 100.94 ± 23.85      | 126.74 ± 23.98       |

Table 3: Comparison of CYP3A4*1G genotype frequency and allele frequency between the two groups.

| Variables | Case (n) | Genotype frequency | Allele frequency |
|-----------|---------|--------------------|------------------|
|           |         | *1/*1              | *1G/*1G          | *1G             | *1               |
| Zhuang    | 48      | 36 (70.5)          | 10 (20.8)        | 2 (4.2)         | 82 (85.4)        | 14 (14.6)          |
| Han       | 47      | 36 (70.5)          | 23 (48.9)        | 19 (40.4)       | 5 (10.6)         | 65 (69.1)          | 29 (30.9)          |
| χ²        | 6.933   |                    |                  |                 |
| P         | 0.031*  |                    |                  |                 |
| Note: *P < 0.05. |

Table 4: Comparison of OPRM1 A118G genotype frequency and allele frequency between the two groups.

| Variables | Case (n) | Genotype frequency | Allele frequency |
|-----------|---------|--------------------|------------------|
|           |         | AA                 | GG               | G                | A                |
| Zhuang    | 48      | 9 (18.8)           | 24 (50.0)        | 15 (31.3)       | 54 (56.3)        | 42 (43.8)          |
| Han       | 47      | 9 (18.8)           | 21 (44.7)        | 19 (40.4)       | 7 (14.9)         | 33 (35.1)          | 61 (64.9)          |
| χ²        | 8.281   |                    |                  |                 |
| P         | 0.016*  |                    |                  |                 |
| Note: *P < 0.05. |

Figure 1: Comparison of Ramsay score and VAS score at different time points after surgery between the two groups.
with different CYP3A4*1G genotypes was also observed. Consistent with the results of previous studies, the difference in sufentanil consumption could probably be caused by the fact that CYP3A4*1G mutation reduces liver microsomal metabolism of sufentanil [20], causing the concentration of sufentanil in the blood to be maintained at a certain level for effective analgesia and leading to a decrease in the need for sufentanil. Zhang et al. [21] observed that sufentanil dosage in patients with CYP3A4*1G mutant homozygotes was also reduced during analgesia after cesarean section. In contrast, we found no difference in sufentanil use in Zhuang patients with different OPRM1 A118G genotype frequencies, indicating that OPRM1 A118G genotype frequency was not associated with sufentanil use in Zhuang patients. Adverse reactions such as nausea and vomiting are common after sufentanil use in postoperative analgesia, and their incidence was shown to be related to the anesthesia methods, surgical types, and drug doses. In this study, we observed no significant difference in the incidence of adverse reactions caused by sufentanil between Zhuang and Han women and among Zhuang or Han women with different genotypes. The underlying mechanisms remain unknown and should be investigated in future studies.

Despite the interesting observations made in this study, there were some limitations. First, as this was a single-center retrospective study, further analysis using multicenter cohorts and prospective settings could provide higher evidence level findings. We only investigated 2 ethnic groups who underwent elective myomectomy in China, and patients from more painful procedures and diverse populations should be investigated in future studies. However, to limit this limitation, we tried to match the patients' baseline characteristics as far as possible. Lastly, no significant difference in the incidence of sufentanil-related adverse reactions could have been related to the relatively small sample size of this study, and therefore, further analysis with larger sample size is required.

5. Conclusion

The SNP of CYP3A4*1G in Zhuang patients in western Guangxi was associated with postoperative analgesia and a lower dosage of sufentanil compared with Han patients. Therefore, patient ethnicity and CYP3A4*1G mutation should be considered when giving postoperative sufentanil analgesia for better analgesic effects.

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| SNPs         | Single nucleotide polymorphisms |
| CYP          | Cytochrome |
| MOR          | Human \(\mu\) opioid receptors |
| ASA          | American Society of Anesthesiologists |
| T1-3         | Indicated time for measuring outcomes |
| VAS          | Visual analog scale |
| PCR-RELP     | Polymerase chain reaction-restriction fragment length polymorphism |
| SD           | Standard deviation |

Data Availability

The datasets used and analyzed in this study are accessible upon request from the corresponding author.
Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Chunying Zhang and Qiyuan Zheng contributed equally to this work.

References

[1] N. Novikov, S. E. Melanson, J. R. Ransohoff, and A. K. Petrides, "Rates of fentanyl positivity in neonatal urine following maternal analgesia during labor and delivery," *The Journal of Applied Laboratory Medicine*, vol. 5, no. 4, pp. 686–694, 2020.

[2] X. R. Cheng, P. G. Xia, Z. Y. Shi et al., "Increased risk of intracranial hemorrhage in preterm infants with OPRM1 gene A118G polymorphism," *Annals of Translational Medicine*, vol. 7, no. 18, pp. 478–479, 2019.

[3] Y. M. Liu, J. L. Lai, and Z. X. Yao, "Anagliss effect of OPRM1 A118G gene polymorphism on sufentanil in patients with hilar cholan-giocarcinoma," *Lingnan Modern Clinics in Surgery*, vol. 19, no. 4, pp. 405–407, 2019.

[4] N. Chen, S. Alimujiang, H. Yang, X. Ma, and G. Xu, "Analysis of effects of gene polymorphisms of cytochrome P450 oxidase 3A4 + 1G and mu-opioid receptor on the analgesic effect of sufentanil in patients undergoing lumbar surgery in Xinjiang," *International Journal of Genetics*, vol. 42, no. 6, pp. 389–396, 2019.

[5] J. Li, X. Wang, C. Ning et al., "Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects," *European Journal of Clinical Pharmacology*, vol. 76, no. 8, pp. 1125–1133, 2020.

[6] W. Zhang, Y. H. Zhang, and Q. C. Kan, "Effect of CYP3A4+1G genetic polymorphism on fentanyl pharmacodynamics in healthy female volunteers," *Chinese Journal of Anesthesiology*, vol. 1, pp. 67–69, 2012.

[7] A. Halikere, J. Moore, R. Hart, J. Tischfeld, and Z. Pang, "Synaptic mechanism of A118G OPRM1 Gene Variants In Human Neurons," *European Neuropsychopharmacology*, vol. 29, no. 3, pp. S732–S733, 2019.

[8] K. M. Kim, S. Choi, D. Kim, J. Lee, and J. W. Kim, "Associations among the opioid receptor gene (OPRM1) A118G polymorphism, psychiatric symptoms, and quantitative EEG in Korean males with gambling disorder: a pilot study," *Journal of Behavioral Addictions*, vol. 8, no. 3, pp. 463–470, 2019.

[9] H. Xie, Q. Q. Fan, Y. Ding, Z. Ma, W. Ge et al., "Effect of OPRM1 A118G and OPRM1 IVS2 + G691C gene polymorphism on fentanyl and dezocine analgesic effect," *Chinese Journal of Clinical Pharmacy*, vol. 29, no. 6, pp. 26–31, 2020.

[10] L. Q. Wu, R. Y. Zhou, Y. C. Wang et al., "Effects of mu-opioid receptor, ATP-banding cassette, subfamily B, member 1 gene, CYP3A genetic polymorphisms on sufentanil consumption in postoperative tumor patients," *International Journal of Anesthesiology and Resuscitation*, vol. 40, no. 7, pp. 622–626, 2019.

[11] H. Zhang, M. Chen, X. Wang, and S. Yu, "Patients with CYP3A4+1G genetic polymorphism consumed significantly lower amount of sufentanil in general anesthesia during lung resection," *Medicine*, vol. 96, no. 4, pp. e6013–e6013, 2017.

[12] J. Guo, F. Yuan, Y. Yang et al., "Genetic polymorphisms of cytokines might affect postoperative sufentanil dosage for analgesia in patients," *Journal of Pain Research*, vol. 13, pp. 1461–1470, 2020.

[13] S. Sandor, Y. Zhang, and J. Xu, "Fungal mitochondrial genomes and genetic polymorphisms," *Applied Microbiology and Biotechnology*, vol. 102, no. 22, pp. 9433–9448, 2018.

[14] D. Pašalić and N. Marinković, "Genetic polymorphisms of the CYP1A1, GSTM1, and GSTT1 enzymes and their influence on cardiovascular risk and lipid profile in people who live near a natural gas plant," *Arhiv za Higijenu Rada i Toksikologiju*, vol. 68, no. 1, pp. 46–52, 2017.

[15] H. Li, X. Gao, H. Zhang et al., "Effect of different background dosages in patient-controlled intravenous analgesia on total demand of sufentanil within 24 hours after surgery," *Chinese Journal of Clinical Medicine*, vol. 27, no. 6, pp. 79–81, 2020.

[16] L. Li, J. F. Zeng, B. C. Hou, W. Liu, Y. Zhan et al., "Effect of cytochrome P450 isofor CYP3A4+1G gene polymorphism on fentanyl dosage and postoperative analgesia in elderly patients with rectal cancer," *The Journal of Practical Medicine*, vol. 34, no. 22, pp. 3705–3708, 2018.

[17] J. Lv, Effect of CYP3A4+1G Polymorphism on Pharmacodynamics of Analgesic Sufentanil after Cesarean Section, Shandong University, 2019.

[18] H. Jiang, "Clinical study of intraspinal analgesia with low-dose drugs on full-term vaginal delivery in re-pregnant women with genotype A118G-AA and previous cesarean section," *Chinese Journal of New Clinical Medicine*, vol. 13, no. 2, pp. 165–166, 2020.

[19] Y. B. Liang, H. Y. Lei, and S. Y. Xu, "Effect of gene polymorphism on postoperative analgesic effect of opioids," *Guangdong Medical Journal*, vol. 38, no. z1, pp. 288–291, 2017.

[20] G. R. Wang, *Relationship between CYP3A4+1G Polymorphism and Sufentanil Pharmacokinetics of General Anesthesia*, Xinxiang Medical University, 2017.

[21] H. Q. Zhang, J. W. Shi, and Z. Y. Meng, "Analogic effect of dezocine combining with sufentanil on patient-controlled intravenous analgesia in patients undergoing cesarean section," *Chinese Journal of Modern Drug Application*, vol. 9, no. 11, pp. 145–146, 2015.